Osiris Therapeutics researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its product Grafix is a cryopreserved placental membrane for treating hard-to-treat acute and chronic wounds, venous leg ulcers, and burns. In addition, the Company offers BIO4, a bone allograft for use in all surgical applications, including spine, trauma, extremity, cranial, and foot and ankle surgery, and Cartiform, a viable chondral allograft that promotes articular cartilage repair to treat focal chondral defects.
Revenue (Q1, 2018)
Gross profit (Q1, 2018)
Gross profit margin (Q1, 2018), %
Net income (Q1, 2018)
EBIT (Q1, 2018)
Market capitalization (31-Oct-2017)
Closing share price (31-Oct-2017)